News

Fabrinet Set to Announce Earnings; Analyst Opinions Surge

Fabrinet Set to Announce Earnings; Analyst Opinions Surge

Fabrinet Earnings Announcement and Analyst Expectations

Fabrinet (NYSE: FN) is preparing to share its earnings results for the first quarter very soon, specifically after the market closes. Analysts are buzzing with anticipation as they predict the company will report earnings of approximately $2.82 per share. This represents a significant increase from the $2.39 per share reported during the same quarter last year.

Projected Revenue Growth

The revenue forecast for Fabrinet is also promising, with estimates hovering around $935.04 million for this quarter, which is notably higher than the $804.23 million reported in the previous year. Such growth projections underscore the optimism surrounding the company's performance in the current economic climate.

Recent Corporate Developments

In a notable shakeup, Fabrinet recently announced the retirement of its founder and Chairman, David T. Mitchell. This development may lead to strategic changes within the company as a new leadership direction is established.

Current Stock Performance

As of last Friday, Fabrinet's stock experienced a slight rise, closing at $440.57—a 0.6% increase. This uptick is reflective of investor confidence as the earnings release approaches, creating a buzz in the stock market.

Insights from Leading Analysts

With the earnings call looming, analysts are weighing in on their expectations for Fabrinet's stock. Here’s a snapshot of how some of the most accurate analysts have rated the company:

JP Morgan's Position

Analyst Samik Chatterjee from JP Morgan retains an Overweight rating and has increased the price target from $345 to $430. Chatterjee boasts an impressive accuracy rate of 79%, signaling confidence in the company's trajectory.

Rosenblatt's Evaluation

Meanwhile, Mike Genovese of Rosenblatt also expresses positivity, maintaining a Buy rating and lifting the price target from $360 to $425. His analytics show an accuracy rate of 81%, indicating strong conviction in Fabrinet's potential.

B. Riley's Analysis

Dave Kang from B. Riley Securities stands firm with a Neutral rating, adjusting the price target from $184 to $220, achieving an accuracy rate of 79%, which reflects a cautious yet optimistic approach to the stock.

Barclays Assessment

Tim Long from Barclays holds an Equal-Weight rating and raises the price target significantly, from $234 to $329. Long's accuracy rate of 72% indicates a measured approach to the stock's current valuation.

Needham's Perspective

Lastly, Ryan Koontz from Needham has reiterated a Buy rating with a price target set at $350, and retains a solid accuracy rate of 75%, bolstering the bullish sentiment around Fabrinet.

Should You Consider Investing in FN Stock?

Given the strong endorsements from various analysts and the favorable earnings forecasts, investors might be contemplating a position in Fabrinet stock. The general sentiment appears to lean positively, with a variety of price targets reflecting substantial upside potential in light of the projected earnings.

Frequently Asked Questions

When will Fabrinet announce its earnings?

Fabrinet is expected to release its earnings after the market closes on the upcoming earnings date.

What are the earnings per share projections for Fabrinet?

Analysts estimate Fabrinet will report earnings of around $2.82 per share for the quarter.

What has been the stock price trend of Fabrinet?

As of the last trading session, Fabrinet’s shares closed at $440.57, reflecting a 0.6% increase.

Who are some of the analysts covering Fabrinet?

Fabrinet is covered by several analysts, including those from JP Morgan, Rosenblatt, B. Riley, Barclays, and Needham.

Is Fabrinet a good investment?

The current analyst ratings and earnings projections suggest that Fabrinet might be a worthwhile investment, given the optimistic predictions around its earnings growth.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cardinal Health Surges with Increased EPS Outlook

Updated Category News Views 111

Cardinal Health's Towering Numbers and Raised Outlook Holy moly, Cardinal Health is strutting out of the gate like they mean business. Their first quarter for fiscal year 2027 showed revenue hitting a hefty $67.5 billion—up 5% from last year. If you're holding NYSE:CAH, you might be grinning ear to ear right now. Cardinal didn’t just squeeze out more revenue; they saw...

Continue Reading
Verismo's SynKIR™-310 Shows Promise in Phase 1 Trials

Updated Category News Views 74

KIR-CAR: A Fresh Take on Cancer Treatment So, Verismo Therapeutics is at it again with their KIR-CAR platform. They're set to present interim data at this year's ASH Annual Meeting. To all those following B-cell non-Hodgkin Lymphoma (B-NHL) treatments, pay attention. SynKIR™-310, a CD19-targeted therapy, is showing some real promise. The science behind this is like...

Continue Reading
Mondego Bio Charges Ahead with Cancer Therapy Trials

Updated Category News Views 78

Cracking Cancer's Code: Mondego's Bold Move Big news from Portugal today—a quiet town called Cantanhede is now the epicenter of a potential game-changer in cancer therapy. Mondego Bio, with its small-molecule innovator MB?388, is diving headfirst into a Phase 1 clinical study. If you're scratching your head about the significance, let me spell it out: this is an attempt...

Continue Reading
Chris Auffenberg Delivers Ford Blue Advantage Gains

Updated Category News Views 18

Can't Ignore Ford's New Strategy in Pre-Owned Cars The auto industry may feel like a runaway train sometimes, and keeping up with the latest turns can be a headache. But here's something catching my eye: Chris Auffenberg Ford's new move with the Ford Blue Advantage certified pre-owned vehicles. It's not just any run-of-the-mill used car deal—this one's got some beef...

Continue Reading
Reviving Carbide Tools: Resharpening for Cost Control

Updated Category News Views 52

Trading Rust: Resharpening Carbide Cutting Tools Alright, picture this: you've got a toolbox full of worn carbide tools, each looking like they've seen better days. You might toss 'em out and grab some new ones, right? But hold on! Carl Ciesla, a cutting tool vet from Sanborn, NY, is talking all about how resharpening could be your ticket to saving a heap of cash and...

Continue Reading
Norwegian Cruise Line's Black Friday Big Splash

Updated Category News Views 65

Jump Aboard NCL's Black Friday Bargain Ship Grab your life jackets, folks! Norwegian Cruise Line (NCL) is sailing with an irresistible Black Friday offer: 50% off all cruises, complete with their much-lauded Free at Sea package. Yeah, if you've been fence-sitting about taking the plunge into the cruise lifestyle, now might just be the time to buckle up your life vests. A...

Continue Reading
Bioactive Research: Converting Science into Guidance

Updated Category News Views 0

Unlocking the Science of Dietary Bioactives Amidst a world swimming in kale smoothies and exotic teas, ILSI U.S. & Canada gathered the sharpest minds to discuss dietary bioactives, an area once shrugged off but now coming into its own. On October 28, 2026, over 250 folks from government, academia, and industry tuned in, looking to understand how these compounds, found in...

Continue Reading
Aker Solutions Lands Big Role in Qatar Oil Upgrade

Updated Category News Views 88

Qatari Venture Beckons Aker Solutions Well, it's not every day you hear about a decades-old oil field getting a facelift, and yet here we are. Aker Solutions has received a nod of approval with a letter of award from PTSC Mechanical and Construction Limited Company (PTSC M&C). This gig is all about the Maydan Mahzam oil field way off the Qatari coast—a legacy site...

Continue Reading
Utility Returns: Short-Term Savings, Long-Term Costs

Updated Category News Views 64

Crunching the Numbers on Utility Returns There's a buzz in the utility sector, and it's not just the hum of power lines—it’s all about return on equity (ROE). Concentric Energy Advisors just dropped some insights that could have us rethinking how these returns play into customer bills and utilities' financing capabilities. What's the Deal with ROE? Think of ROE like a...

Continue Reading
Qfin Faces Stock Lawsuit: Know Your Investor Rights

Updated Category News Views 82

Qfin in the Legal Hot Seat When you hear about a company's legal wranglings, especially one like Qfin Holdings, Inc., you've got to sit up and take notice. We're not talking about a quick scuffle here; this is a full-blown class action lawsuit with its talons sunk deep into allegations of securities law violations. They're squared off against DJS Law Group, an outfit that...

Continue Reading

Top 5 Most Recently Viewed Articles

M-DAQ Expands Footprint: Eyes Vietnam's Booming Economy

Updated Category News Views 51

Strategic Moves in the ASEAN Financial Arena Now, this one's got some bite to it. M-DAQ Global's foray into Vietnam isn't just another step on the fintech ladder - it's a bold expansion play into one of ASEAN's fastest up-and-comers. Forget the usual corporate fluff; what we're seeing here is a calculated strike to grab a piece of a pie that's only getting bigger. Why...

Continue Reading
IDEAYA Biosciences, Inc. Reports Strong Progress in 2024

Updated Category News Views 194

IDEAYA Biosciences, Inc. Achieves Significant Milestones in Financial Reporting IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a pioneering precision medicine oncology company, recently shared its financial results for the fourth quarter and the full year of 2024. The company is dedicated to the discovery and development of targeted therapeutics, making noteworthy strides...

Continue Reading
5N Plus Inc. Enhances Supply Partnership with First Solar

Updated Category News Views 256

Introduction to the New Supply Agreement 5N Plus Inc. (TSX: VNP), a global leader in specialty semiconductors and performance materials, recently announced a major expansion of its supply agreement with First Solar, Inc. (NASDAQ: FSLR). This partnership is vital in supplying increased volumes of critical materials essential for the production of photovoltaic solar...

Continue Reading
Energy Services of America Shines at Upcoming Investor Conference

Updated Category News Views 162

Highlighting Energy Services of America's Upcoming Investor Conference Energy Services of America (NASDAQ: ESOA) is preparing to make a significant impact at an upcoming investor conference. The event will feature presentations by the company's top executives, providing insights into the organization’s future strategies and objectives. Key Presenters at the Conference...

Continue Reading
Ophthalmic Drugs Market Expected to Hit $67.83 Billion by 2033

Updated Category News Views 51

Overview of the Ophthalmic Drugs Market The ophthalmic drugs market is experiencing impressive growth, largely due to the increasing prevalence of eye diseases and innovative advancements in drug development. In 2023, the market was valued at USD 37.17 billion and is expected to grow at a remarkable CAGR of 6.2% from 2024 to 2033, surpassing USD 67.83 billion. Recent...

Continue Reading